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Abstract
Background: Phase III randomized controlled trials (RCT) typically exclude certain patient subgroups, thereby
potentially jeopardizing estimation of a drug’s effects when prescribed to wider populations and under routine care
(“effectiveness”). Conversely, enrolling heterogeneous populations in RCTs can increase endpoint variability and
compromise detection of a drug’s effect. We developed the “RCT augmentation” method to quantitatively support
RCT design in the identification of exclusion criteria to relax to address both of these considerations. In the present
manuscript, we describe the method and a case study in schizophrenia.
Methods: We applied typical RCT exclusion criteria in a real-world dataset (cohort) of schizophrenia patients to
define the “RCT population” subgroup, and assessed the impact of re-including each of the following patient
subgroups: (1) illness duration 1–3 years; (2) suicide attempt; (3) alcohol abuse; (4) substance abuse; and (5) private
practice management. Predictive models were built using data from different “augmented RCT populations” (i.e.,
subgroups where patients with one or two of such characteristics were re-included) to estimate the absolute
effectiveness of the two most prevalent antipsychotics against real-world results from the entire cohort.
Concurrently, the impact on RCT results of relaxing exclusion criteria was evaluated by calculating the comparative
efficacy of those two antipsychotics in virtual RCTs drawing on different “augmented RCT populations”.
Results: Data from the “RCT population”, which was defined with typical exclusion criteria, allowed for a prediction
of effectiveness with a bias < 2% and mean squared error (MSE) = 5.8–6.8%. Compared to this typical RCT, RCTs
using augmented populations provided improved effectiveness predictions (bias < 2%, MSE = 5.3–6.7%), while
returning more variable comparative effects. The impact of augmentation depended on the exclusion criterion
relaxed. Furthermore, half of the benefit of relaxing each criterion was gained from re-including the first 10–20% of
patients with the corresponding real-world characteristic.
Conclusions: Simulating the inclusion of real-world subpopulations into an RCT before running it allows for
quantification of the impact of each re-inclusion upon effect detection (statistical power) and generalizability of trial
results, thereby explicating this trade-off and enabling a controlled increase in population heterogeneity in the RCT
design.
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Background
Patient populations recruited in phase III
randomized-controlled trials (RCT) tend to be more
homogeneous compared to those likely to be prescribed
the drug under investigation in real-world clinical prac-
tice. Such homogeneity is the result of excluding patients
with certain characteristics, such as comorbidities, risk
factors or co-medications. This practice may comprom-
ise the generalizability of results to real-world patient
populations [1, 2]. For example, Heng et al. [3] found
that more than a third of real-world patients with meta-
static renal cell carcinoma are ineligible for clinical trials,
showing poorer outcomes than patients enrolled in such
clinical trials. In schizophrenia, an even higher propor-
tion of screened patients (73–93%) has been reported as
not participating in clinical trials [4–7]. It is often
unknown how trial exclusion criteria impact estimations
of drug effects, possibly exaggerating or underestimating
them [8, 9] and, in general, there is no evidence at time
of launch to support treatment guidance for (real-world)
patients who were excluded from trials conducted as
part of the process of drug approval [10]. Predictive
models can be used to extrapolate the drug effect from
RCT into effectiveness in the broader real-world popula-
tion [11]. However, such model predictions are only as
good as the underlying data (or assumptions) on the way
the new drug effect is modulated by different real-world
patient characteristics. In particular, predictions of drug
effects on patient subgroups with a characteristic of a
categorical nature, such as having a comorbidity or not,
can be poor whenever the subgroup has been fully
excluded from RCTs, implying that no data exist on the
interaction of the drug and the patient subgroup. Press-
ler and Kaizar [12] have developed a method relying on
real world data to estimate the gap between RCT effi-
cacy and real world effectiveness, which they term “RCT
generalizability bias”. However, considerations of RCT
design, such as constant sample sizes and the necessary
trade-off between minimizing this “RCT generalizability
bias” and retaining enough RCT statistical power re-
mains unexplored.
While it is essential for all stakeholders - drug manu-
facturers, payers, clinical practitioners, and patients -
that drug development trials provide as much informa-
tion as possible on real-world effectiveness, fully repre-
sentative populations are not currently included in trials
due to concerns about patient safety, ethics, and the
ability to detect a drug effect from a relatively small and
controlled sample of patients. A more heterogeneous
trial population could indeed add variability to the trial
endpoint(s) and/or lead to smaller average treatment
differences between arms, that is, to smaller effect sizes,
which require larger populations to attain the same
statistical power [13–15]. While larger trials are costlier,
endpoints with a higher variability may translate in trials
that take longer to read out [16]. In addition, recruiting
certain types of population may require additional efforts
[17]. Ultimately, trialists need to strike a high-stake
compromise between representativeness, that is, the
RCT’s external validity, and confidence in obtaining the
desired effect sizes from a trial enrolling a set number of
patients (internal validity).
Considering this, we developed a novel modeling and
simulation method, the “RCT augmentation” method, to
support the design of RCTs. The method uses real-world
data to simulate the impact of including certain patient
populations typically excluded from phase III RCT on:
(1) the ability to detect the investigational drug efficacy,
i.e., the RCT’s statistical power, and (2) the accuracy of
predictions of the drug’s effectiveness, i.e., how accur-
ately the data to be collected in the RCT will enable
subsequent prediction of the drug effects in routine care.
The objective of our work was to test and validate this
method through implementation of a case study in schizo-
phrenia. Namely, we quantified the impact of re-including
certain real-world patients typically excluded from Phase
III trials in schizophrenia (i.e., by broadening inclusion
criteria) upon both the assessment of antipsychotic drug
effects and the prediction of their effectiveness.
Methods
The “RCT augmentation” method
General methodology
The “RCT augmentation” method aims at supporting
RCT design by quantifying the trade-off between par-
tially relaxing certain exclusion criteria to collect the
most informative data to predict treatment’s real-world
effects, while preserving the trial’s statistical power. The
method requires real-world data (e.g., observational
cohort, disease registry, electronic healthcare records,
claims databases) on patient characteristics and treat-
ment outcome in the indication of interest. Several
scenarios (virtual RCTs, augmented or not) are tested
through simulations using these real-world data to quan-
tify the impact of using different population eligibility
criteria for the planned RCT. All virtual RCTs, aug-
mented or not, have an identical target sample size.
Operationally, augmented RCTs correspond to trials
where the protocol allows for inclusion of the subset of
patients that meets the relaxed criterion or criteria,
while keeping all other, remaining exclusion criteria. The
main results of the augmented RCTs are obtained as for
regular RCTs, i.e., by calculating the primary (and
secondary) endpoints on all enrolled patients.
Terminology
The subset of patients susceptible to take the drug of
interest, once it becomes available on the market, is
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termed hereafter “real-world population”. Applying typ-
ical RCT exclusion criteria to this population returns the
“RCT population” subset. Replacing a part of patients
from the RCT population by patients meeting relaxed
exclusion criteria creates “augmented RCT populations”.
The target estimand of effectiveness prediction models is
the drug effectiveness in the real world population, while
the (augmented) RCT estimand is the drug efficacy in
the (augmented) RCT population.
Step-by-step implementation
After selection of an appropriate real-world data source,
the “RCT population” is first generated by applying
exclusion criteria traditionally used in RCTs for the indi-
cation of interest to the “real-world population”. The
representativeness of a typical RCT (i.e., using traditional
inclusion/exclusion criteria) can be first judged at this
stage by comparing the distribution of patient character-
istics and outcomes between the “RCT population” and
the “real-world population”.
Second, the exclusion criteria that could potentially be
relaxed, at least partially, are identified and listed. By
contrast, exclusion criteria that are necessary for safety
or ethical reasons are not considered.
Third, virtual RCT scenarios are tested, in which
various patients subgroups are “re-included” in a
controlled proportion by relaxing exclusion criteria one
by one or two by two. These “re-inclusions” are
performed at constant RCT size, that is, by replacement,
to keep subsets of identical patient size and keeping
other exclusion criteria fixed. This broadens the RCT
population and creates a range of “augmented RCT
population” subsets. The augmentation is done by
replacement to keep subsets of identical patient size and
facilitate their comparison. For each RCT scenario,
predictive models of the outcome of interest (endpoint for
the trial or a proxy for it) are built successively on data
from the “RCT population” or the different “augmented
RCT” populations and predictions compared to the
outcome in the full real-world population. The method is
agnostic to the type of model chosen for effectiveness
prediction, which can range from simple multivariate
regression to more advanced models. This comparison of
predicted versus observed outcomes enables a thorough
appraisal of the representativeness of each (augmented)
RCT population and of its expected usefulness in accurately
predicting the new drug’s effectiveness (external validity).
At the same time, virtual RCTs with the envisaged
sample size are built using patients from either “RCT
population” or the different “augmented RCT popula-
tions”. They enable to calculate the distribution of
possible trial results for each of these source populations
(efficacy or comparative efficacy), which in turns allows
for calculation of the trial’s statistical power.
Ultimately, the method provides trialists with both
the increase in representativeness, if any, and the
change in statistical power (equals the ability to
detect a given effect size) for each augmentation in a
particular type of real-world patients. In other words,
the method quantifies the impact of amending the
trial protocol to relax one or two exclusion criteria,
possibly partially only, on representativeness and trial
statistical power. The trade-off between these two
goals of Phase III RCTs can then be chosen in a
controlled and informed manner.
Case study: Population selection for phase 3 RCTs in
schizophrenia
Data source
The present case study used observational patient-level
data from the Schizophrenia Outpatients Health Out-
comes (SOHO) study, [18, 19] a prospective cohort
study addressing symptom improvement, associated with
the introduction or switch of antipsychotic drugs in
schizophrenia outpatients, that is, patients managed in
ambulatory or community settings. The SOHO study
followed 10,218 adults with schizophrenia from across
ten European countries over a 3-year period. All the
participants initiated or switched antipsychotic drug
therapy at baseline. Use of concomitant medications was
allowed during the study, but not reported by physicians.
Data on demographics, clinical status, functioning, use
of other psychotropic drugs and adherence to the
previously-used drug were collected during routine visits
at baseline, 3, 6, and 12 months. For the present case
study, due to confidentiality agreements, the names of
antipsychotic drugs were anonymized by assigning each
a letter (drug D1, drug D2, drug D3, etc.). In addition, in
an effort to avoid drug identification through given
doses, these were converted into the equivalent defined
daily dose (DDDeq) by dividing the prescribed dose by
the World Health Organization (WHO)’s defined daily
dose [20].
The SOHO cohort was assumed to be representative
of schizophrenia patients as managed in routine care,
and change in symptoms severity was assumed to reflect
the real-world effect of the newly-initiated antipsychotic
drug for each patient. In our study, baseline and
3-month data were used. Any change in the Clinical
Global Impression – Severity score (CGI-S, using a
7-point score) at 3 months after the last adjustment of
antipsychotic treatment (new treatment or switch at
baseline) was registered as a change in symptoms
(ΔCGI-S, change in symptoms hereafter). This change in
symptoms was assumed to represent the real-world
effect of the newly-initiated antipsychotic drug. The
earliest available time point (3 months) of the outcome
was selected to facilitate the comparison of results with
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previously-published RCTs, the majority of which do not
report data beyond this period [21]. In addition, only
patients starting on one of the two most-frequently used
antipsychotic drugs (D1 or D2) in SOHO at baseline (N
= 5591 for D1 and 2188 for D2) were selected to gener-
ate two treatment groups. Patients were grouped by type
of newly-initiated drug (D1 or D2). The methods
employed below were identical for drug D1 and D2.
Exclusion criteria of interest and construction of the “RCT
population”
First, exclusion criteria traditionally used in Phase III
RCTs in schizophrenia were identified using a
meta-analysis of more than 200 antipsychotic clinical tri-
als in schizophrenia [22] and a literature research on
pivotal Phase III RCTs across ClinicalTrials.gov, EU
Clinical Trials Register, WHO International Clinical Tri-
als Registry Platform (WHO ITCRP), and PubMed
websites, which returned 30 trials on eight different
second-generation antipsychotic drugs marketed since
1991 [23]. The strictest inclusion thresholds were used
to define the criteria most commonly used. The identi-
fied exclusion criteria were: (1) Illness duration < 3 years;
(2) History of suicide attempt (a proxy for risk of suicide
attempt and for depression); (3) History of alcohol
abuse; (4) History of drug abuse; (5) Non-compliance
according to the physician and (6) Patients followed by a
psychiatrist who practices only in a private setting
(“private practice patients” hereafter) The last exclu-
sion criterion listed above, while not an explicit
exclusion criterion, reflected the fact that physicians
enrolling patients for RCTs usually practice at least
partially in a public setting, such as a university hos-
pital. In the end, the “RCT population” for each drug
group resulted from applying the six exclusion criteria
above to the SOHO population. No other exclusion
criteria were applied; in particular, criteria related to
safety or relying for their definition on variables not
present in the SOHO database were not used.
Second, we applied these 6 exclusion criteria to the
SOHO population to exclude patients for each drug
group (starting either D1 or D2) to define a “RCT
population” for D1 and D2 (Fig. 1). Change in symp-
toms in the RCT population carved out from SOHO
fell within a similar range to those from six RCT studies
identified in the literature (see details in Additional file 1:
section 3 “Comparison of CGI-S from the “RCT popula-
tion” subset with values obtained for RCTs published in
the literature”).
Analyses, modeling and simulations
Several virtual Phase III RCTs in schizophrenia were
simulated by using different exclusion criteria to assess
modeling predictions obtained against real-world out-
comes from SOHO (Table 1). The “RCT population aug-
mentation” aimed at selectively increasing the population’s
heterogeneity, thereby creating a series of “augmented
RCT populations”. Namely, a set number of patients from
the “RCT population” were randomly replaced by an equal
number of originally excluded patients (Fig. 1); all
re-included patients fulfilled the six above-listed exclusion
criteria except one, which was replaced by one of the
following relaxed criteria:
 Patients with illness duration between 1 and 3 years
 Patients with one past suicide attempt
 Private practice patients
 Patients with history of alcohol abuse
 Patients with history of drug abuse
Fig. 1 Definition of the different populations used for analysis and predictive modeling. The process was repeated for the most-frequently
initiated drugs in SOHO, D1 and D2
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As a result, a series of five types of augmented RCT
populations were obtained. Please note that the exclu-
sion criteria above were relaxed in a “controlled” manner
so that re-inclusion of patients meeting the criteria was,
a priori, safe and feasible. For example, including all
patients who have attempted suicide could be difficult to
manage in a trial if allowing the inclusion of patients
with 10+ suicide attempts. As a result of controlling
exclusion criteria, we selectively opened the trial to pa-
tients with a single past suicide attempt only. Similarly,
enrolling patients recently diagnosed with schizophrenia
into a clinical trial of a new drug is unlikely, given the
large number of effective first-line therapies available on
the market; therefore, only patients who have experienced
the condition for longer than 1 year were considered for
re-inclusion. For similar reasons, patients were not
enrolled if they were non-compliant.
Besides the five types of augmented RCT populations
selected as described above, three additional augmented
RCT populations were created by relaxing two selected
criteria at the same time:
 Patients with illness duration between 1 and 3 years
and/or one past suicide attempt
 Patients with illness duration between 1 and 3 years
and/or private practice patients
 Patients with illness duration between 1 and 3 years
and/or history of alcohol abuse
Table 1 Relative sizes of patient populations and outcomes across population types
Population type % increase in RCT-eligible patient pool
(95% CIc)
Outcome Average ΔCGI-S
(95% CId)
Patients initiating drug D1
“Real-world population” (SOHO cohort) – −0.88 (− 0.90, − 0.85)
“RCT population” (22.6% of SOHO cohort patients) 0 − 0.78 (− 0.83, − 0.72)
Augmented RCT populations:
Patients with illness duration between 1 and 3 yearsa 17.9% (15.5, 20.5%) −1.04 (− 1.18, − 0.89)
Patients with one past suicide attempta 18.1% (15.7, 20.8%) − 0.94 (− 1.08, − 0.81)
Private practice patientsa 14.7% (12.6, 17.1%) −1.03 (− 1.15, − 0.90)
Patients with history of alcohol abusea 6.3% (5.0, 7.8%) −0.60 (− 0.79, − 0.42)
Patients with history of drug abusea 5.6% (4.4, 7.0%) −0.78 (− 0.99, − 0.57)
Patients with illness duration between 1 and 3 years and/or one past
suicide attemptb
37.7% (34.0, 41.9%) −1.00 (− 1.10, − 0.90)
Patients with illness duration between 1 and 3 years and/or private
practice patientsb
35.1% (31.4, 39.0%) −1.05 (− 1.15, − 0.96)
Patients with illness duration between 1 and 3 years and/or history of
alcohol abuseb
25.0% (22.1, 28.3%) − 0.93 (− 1.05, − 0.81)
Patients initiating drug D2
“Real-world population” (SOHO cohort) – −0.71 (− 0.75, − 0.67)
“RCT population” (25.7% of SOHO cohort patients) 0 −0.64 (− 0.72, − 0.57)
Augmented RCT populations:
Patients with illness duration of 1–3 yearsa 11.7% (8.9, 15.1%) −0.77 (− 1.03, − 0.51)
Patients with one past suicide attempta 15.8% (12.6, 19.8%) −0.57 (− 0.71, − 0.42)
Private practice patientsa 14.9% (11.7, 18.7%) −0.74 (− 0.93, − 0.55)
Patients with history of alcohol abusea 8.7% (6.4, 11.6%) −0.63 (− 0.97, − 0.30)
Patients with history of drug abusea 4.3% (2.8, 6.5%) −0.50 (− 0.83, − 0.17)
Patients with illness duration between 1 and 3 years and/or one past
suicide attemptb
29.4% (24.5, 35.0%) −0.62 (− 0.76, − 0.49)
Patients with illness duration between 1 and 3 years and/or private
practice patientsb
29.6% (24.7, 35.2%) −0.79 (− 0.94, − 0.64)
Patients with illness duration between 1 and 3 years and/or history of
alcohol abuseb
20.5% (16.7, 25.1%) −0.73 (− 0.93, − 0.52)
aplus meeting the remaining 5 RCT eligibility criteria. bplus meeting the remaining 4 RCT eligibility criteria; cThe Clopper-Pearson interval was used to calculate the
95% confidence interval; CI confidence interval; dThe confidence interval (CI) was calculated under the assumption that ΔCGI-S had a normal distribution
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Again, simultaneously relaxing two criteria as above
was acceptable as it did not compromise safety a priori
(which could be the case for example when combining
past suicide attempts and drug abuse), while seeming
operationally feasible a priori also.
Predictive model building and simulation study
Real-world change in symptoms at 3 months was pre-
dicted using a model of the symptom score at 3 months,
CGI-S, and subtracting the baseline score. The outcome
(CGI-S) is an ordered categorical variable, measured on
a 7-point scale. It was therefore modeled using a latent
variable, to which an ordinal logistic regression model
was applied [24]. The regression variables used to fit the
model included all of 24 variables available in SOHO:
patient characteristics, baseline symptoms, and drug
dosages (see subsection 1.3. Predictive model in Add-
itional file 1 for further details). This statistical model
was trained using the newly-built data from the “RCT
population” or “augmented RCT populations”, that is,
the model estimated for each population a different set
of cut-offs for the latent variable. The same model struc-
ture, including all regression variables, was used across
all the analyses; models differed only in terms of the data
used to train them (i.e., the RCT or augmented RCT
populations used as training sets). This way, differences
in model predictions were only attributable to the data
used to train it (i.e., data originating from the RCT or
the augmented RCT populations) and not its structure.
The model was then used to simulate change in symp-
toms in the SOHO population using only baseline values
from SOHO patients. We compared predictions across
changes in symptoms observed for the whole real-world
population, using the SOHO population as test set for
external validation. Specifically, bias and mean squared
error (MSE) of predictions were calculated to gauge how
re-including patients with specific characteristics could
improve real-world outcome predictions made using
RCT data only (see equations in Additional file 1: Defin-
ition of bias and MSE for model predictions). Bias and
MSE tend towards zero as prediction performance im-
proves, that meaning the distribution of predicted
changes in symptoms in the real-world population be-
comes closer to its actual distribution as observed in the
full SOHO cohort. For each selected exclusion criterion,
we tested a series of augmentation percentages. The
number of replaced patients was increased gradually
until the percentage of patients with that specific
characteristic reached “natural augmentation”. “Natural
augmentation” was defined as the proportion of
real-world patients in a population including all patients
meeting the relaxed criterion and the five remaining
exclusion criteria, without stratified randomization at
patient enrollment.
Comparative efficacy in virtual, augmented RCTs
In addition, to assess how population augmentation
impacted trial results, the comparative efficacy obtained
from virtual Phase III RCTs with two parallel arms in
which 500 patients initiated either of the two most
prevalent drugs (D1 and D2) was computed (Fig. 2). A
robust estimate of comparative efficacy is indeed what
trialists rely on to calculate the trial’s statistical power.
First, 250 patients from the “augmented RCT popula-
tion” started on drug D2 (as defined previously) were
randomly selected. Next, another 250 patients who
started on drug D1 were selected from the equivalent
“augmented RCT population” by propensity score
matching (see subsection 1.2 for methodological details
in Additional file 1). We compared the average change
in symptoms between these 250-paired patients, which
was termed the comparative efficacy of D1 vs. D2 for
the virtual trial. To reduce the effects of random
sampling errors, sampling and matching were re-
peated to evaluate 1000 virtual Phase III RCT samples
(bootstrapping) for each relaxed criterion, i.e., for
each RCT population augmentation. Comparative
efficacy was reported as the distribution of these 1000
sampling results. In addition, the same repeated
process of selection and matching was also applied to
the entire SOHO population to obtain comparative
effectiveness of drug D1 vs. D2 (Fig. 2). Further
details on calculation of comparative efficacy can be
found in Additional file 1: Section 1.2).
We used R (version 3.1.2) for all analyses [25].
Results
Differences between real-world and RCT populations in
schizophrenia
Applying all six exclusion criteria typical of Phase III
trials to the SOHO real-world population left only 22.6
and 25.5% of patients initiating drug D1 and drug D2,
respectively, eligible for inclusion in the “RCT popula-
tion”. For both drugs, the magnitude of symptoms
improvement was greater in the SOHO population com-
pared to the “RCT population” (Drug D1: − 0.88 (− 0.90,
− 0.85) vs. -0.78 (− 0.83, − 0.72); Drug D2: − 0.71 (− 0.75,
− 0.67) vs. -0.64 (− 0.72, − 0.57), see Table 1).
The size of the subpopulations to be re-included in
the “RCT population” differed depending on the
exclusion criterion relaxed (Table 2 and Table 3).
Namely, opening the trial to patients with shorter
illness duration (1–3 years), one past suicide attempt
or to private practice patients enabled to tap into a
wider patient pool than opening the trial to patients
with alcohol or drug abuse, e.g., among patients
taking D1, the patient pool was increased by 188
(shorter illness duration), 190 (past suicide attempt)
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and 159 (private practice) patients compared to 73
(alcohol) and 65 (drug abuse) patients.
Different subpopulations considered for re-inclusion
exhibited different outcomes (as measured by the
ΔCGI-S). As expected, certain subpopulations tended to
benefit more from treatment: patients with illness dur-
ation between 1 and 3 years or private practice patients;
their re-inclusion into the trial was tapping into a popula-
tion having on average a more favorable ΔCGI-S than the
average score obtained in the original “RCT population”.
Predictions of real-world effects from RCT population
data
Using data from the “RCT population” alone yielded
prediction models for real-world effects of D1 and D2
associated with a bias of 0.054 and − 0.016 and an MSE
of 0.85 and 0.78 for participants under drug D1 and D2,
respectively (values for x = 0 in Fig. 3). That is, the abso-
lute value of the bias represented less than 2 % of the
average real-world CGI-S at 3 months (0.054/3.54 = 1.5%
under drug D1 and 0.016/3.67 = 0.4% under drug D2),
Fig. 2 Calculation of comparative efficacy of drug D1 vs. D2 obtained from virtual Phase III RCTs. This calculation is repeated for each type of RCT
population augmentation (= each relaxed criterion)
Table 2 Comparison of the impact of relaxing different eligibility criteria in patients taking drug D1
Re-included subpopulations Natural augmentation (number of patients re-included
when opening the trial to the specific “real-world popu-
lation” subgroup)
Prediction bias
with natural
augmentation
Mean squared error (MSE) of
prediction with natural
augmentation
Relaxed
eligibility
criteria
Illness duration between 1
and 3 years
188 0.033 0.818
1 past suicide attempt 190 0.057 0.820
Private practice 159 0.041 0.830
Alcohol abuse 73 0.054 0.836
Drug abuse 65 0.053 0.833
Illness duration between 1
and 3 years + 1 past suicide
attempt
339 0.024 0.803
Illness duration between 1
and 3 years + private
practice
321 0.024 0.814
Illness duration between 1
and 3 years + alcohol
abuse
248 0.037 0.812
RCT population not applicable 0.054 0.852
SOHO “real-world population” not applicable 0.000 0.000
Results for the “RCT population” and SOHO “real-world populations” are displayed as benchmark
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while the MSE of the prediction represented about 6–7%
of the average of squared real-world CGI-S values at
3 months (0.85/12.53 = 6.8% under drug D1 and 0.78/
13.47 = 5.8% under drug D2).
The augmentation of the “RCT populations” initiating
drug D1 or D2 by relaxing any of the pre-selected eight
exclusion criteria led to improvement of the prediction
of real-world effects in terms of MSE (6.4–6.7% under
drug D1, 5.3–5.6% under drug D2). The bias remained
under 2%. A more heterogeneous RCT population
yielded, as expected, better predictions of real-world ef-
fects (see Fig. 3a and Table 2 for RCT populations initi-
ating drug D1, Fig. 3b and Table 3 for RCT populations
initiating drug D2).
Upon relaxing any of the eight exclusion criteria, we
first observed a decrease in MSE as a result of augment-
ing the “RCT population” through the inclusion of
patients with real-world characteristics (Fig. 3). As more
real-world patients were re-included, the decrease in
MSE became gradually weaker. In other words, benefit
in terms of effectiveness prediction is mostly gained
from re-including the first few real-world patients from
each subpopulation.
As shown in Fig. 3, Tables 2 and 3, re-inclusion of dif-
ferent real-world subpopulations contributed differently
to improving prediction. Re-including patients with ill-
ness duration between 1 and 3 years and/or with one
past suicide attempt (with natural augmentation)
returned the most accurate prediction (lowest MSE,
corresponding to an improvement in MSE of 0.803
(5.8%) and 0.716 (4.9%) for drug D1 and D2, respect-
ively, see Tables 2 and 3). Among eligibility criteria
relaxed as single elements, patients with illness duration
between 1 and 3 years yielded the most accurate predic-
tion (see Tables 2 and 3). Note that using these eligibility
criteria also enabled to re-include patients from the
larger subpopulation pools, that is, from the “augmented
RCT populations” of larger sizes, and/or the subpopula-
tion pools with the larger change in symptoms (see Table
1).
Comparative efficacy in virtual RCTs using augmented
populations
We simulated virtual RCTs comparing drug D1 and D2
to estimate how the evaluation of comparative efficacy
would be impacted when augmenting trial populations,
a strategy which could add variability in the outcome
and change its estimation in RCTs. Comparative effective-
ness of drug D1 vs. D2, which we calculated by propensity
score matching on the real-world data, was found to favor
drug D1 over D2; the change in symptoms under D1 was
− 0.12 ± 0.08 points larger for D1 than D2 (not
clinically-significant). Comparative efficacy as measured in
virtual RCTs with six standard exclusion criteria was less
favorable to D1, with a change in symptoms for D1 vs. D2
of − 0.07 ± 0.06 points (Fig. 4 and Table 4).
Average comparative efficacy increased when
re-including specific real-world patients (i.e., it was more
favorable to D1 vs. D2, thereby closer to the real-world
comparative effectiveness) across all of the augmented
RCT population tested, except for augmentation using
patients with a history of alcohol or drug abuse where it
was almost unchanged (Table 4). Virtual trials that
returned a comparative efficacy closest to comparative
effectiveness were trials with populations augmented in
patients with one past suicide attempt (comparative
Table 3 Comparison of the impact of relaxing different eligibility criteria in patients taking drug D2
Re-included subpopulations Natural augmentation (when opening the trial
to the specific “real-world population”
subgroup)
Prediction bias with
natural
augmentation
Mean squared error (MSE) of
prediction with natural
augmentation
Relaxed
eligibility
criteria
Illness duration between 1
and 3 years
56 0.004 0.733
1 past suicide attempt 73 0.013 0.734
Private practice 69 0.003 0.737
Alcohol abuse 42 −0.008 0.749
Drug abuse 22 −0.004 0.756
Illness duration between 1
and 3 years + 1 past suicide
attempt
121 0.033 0.716
Illness duration between 1
and 3 years + private practice
121 0.009 0.719
Illness duration between 1
and 3 years + alcohol abuse
90 0.011 0.728
RCT population not applicable −0.016 0.777
SOHO “real-world population” not applicable 0.000 0.000
Results for the “RCT population” and SOHO “real-world populations” are displayed as benchmark
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efficacy of − 0.122 ± 0.064 points) and trials augmented
in patients with illness duration between 1 and 3 years
and/or private practice patients (comparative efficacy of
− 0.127 ± 0.071 points). The standard deviation of com-
parative efficacy varied from 0.06 in the RCT population
to 0.08 in SOHO, with intermediate values for aug-
mented trials.
Discussion
We report the development and testing of a novel mod-
eling and simulation method, the “RCT augmentation”
method, enabling trialists to select inclusion/exclusion
criteria based on an estimation of the impact that this
population selection will have on (1) the trial’s results
and (2) the trial’s ability to inform on the effectiveness of
the investigational drug (i.e., provide data that best pre-
dicts the drug’s effectiveness). The trial results (i.e., the
calculated distribution of comparative efficacy from
virtual RCTs) can be directly used to calculate the trial’s
statistical power, and thereby its ability to detect effect
sizes for the studied endpoint.
Key findings
The present case study provides preliminary information
on the scope and application of the method. First, our
results suggest that relaxing certain eligibility criteria
(i.e., including a part of the real-world patients in the
“RCT population”) provide RCT results of comparative
efficacy that are closer to comparative effectiveness,
thereby narrowing the “efficacy-to-effectiveness gap”. In
addition, data obtained from these augmented RCTs can
be used to improve effectiveness predictions using mod-
eling (lowering the MSE, bias remaining < 2%). In our
case study, the comparative efficacy improved with
population augmentation because comparative treatment
effect on patients excluded – as a result of applying
Fig. 3 Mean squared error of the prediction from model fitted to data from augmented RCT populations of patients initiating drug D1 (a) or
drug D2 (b). The augmentation was performed by re-including, through random replacement within the RCT population, an increasing number
of patients (x-axis) from eight different real-world subpopulations (colored markers) until the natural percentage of the patients with that specific
characteristic was reached (right end of each curve). Each point represents an average of 500 random samplings of re-included patients
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certain criteria – was on average better than that
measured for the “RCT population”. In cases where
comparative effectiveness (or effectiveness) would be on
average lower than comparative efficacy (or efficacy), a
decrease in trial statistical power is expected with
population augmentation, along with the gain in
precision for real-world effects. In these cases as well,
our method enables to quantify the terms of the com-
promise to be made between trial’s results (comparative
efficacy, including its variability) and effectiveness pre-
diction/representativeness. Our results reiterate findings
from studies conducted in other indications that
Fig. 4 Comparative efficacy of virtual RCTs comparing drug D1 and drug D2, in two parallel study arms with 250 patients each. Source
populations are displayed on the x-axis: RCT or augmented RCTs as a result of relaxing any of the eight eligibility criteria. Comparative
effectiveness is reported for the real-world population in the full SOHO cohort. Each box plot represents the distribution of comparative efficacy
values obtained for the 1000 sampling replicates (bootstrapping)
Table 4 Comparative efficacy of virtual RCTs comparing drug D1 and drug D2
Re-included subpopulations Average comparative efficacy of D1 vs.
D2 (ΔCGI-S for D1 minus ΔCGI-S for D2)
Standard deviation of comparative efficacy D1 vs.
D2 (ΔCGI-S for D1 minus ΔCGI-S for D2)
Relaxed eligibility
criteria
Illness duration between 1
and 3 years
− 0.113 0.067
1 past suicide attempt −0.122 0.064
Private practice −0.092 0.064
Alcohol abuse −0.064 0.066
Drug abuse −0.066 0.064
Illness duration between 1
and 3 years + 1 past
suicide attempt
− 0.171 0.072
Illness duration between 1
and 3 years + private practice
− 0.127 0.071
Illness duration between 1
and 3 years + alcohol abuse
− 0.110 0.067
RCT population −0.066 0.062
SOHO “real-world
population”
−0.124 0.084
The results were generated in two parallel study arms with 250 patients each
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exploring outcomes in real-world patient subgroups can
better inform predictions of real-world effects for the
population as a whole [26]. The two factors driving
improvement in predicting real-world effects (i.e., lower-
ing MSE while keeping bias < 2%) were found to be 1) a
larger size of the subpopulation of real-world patients
originally excluded and 2) better outcomes in these
subpopulations (i.e., outcomes closer to those obtained
for the full real-world population). Similarly, we found
that RCTs returned comparative efficacy results that are
more variable if augmented in real-world populations, as
previously demonstrated in the general case [13–15].
Second, our results show that applying six of the
eligibility criteria most typically used for RCTs in schizo-
phrenia (namely, illness duration < 3 years, history of
suicide attempt, of alcohol or drug abuse, non-compliant
patients according to the physician, private practice
patients) to the SOHO population, considered to repre-
sent real-world schizophrenia patients, resulted in the
exclusion of more than three quarters of patients. While
in accordance with the documented need to conduct
effectiveness studies for antipsychotic drugs, [27] the
high percentage of patients currently excluded from
drug development trials in schizophrenia is worth
noting. In addition, the sample size of excluded patients
presented here needs to be interpreted in the light of
knowledge that RCTs in schizophrenia may employ even
more exclusion criteria than those applied in our study.
In our study, it was not possible to apply all exclusion
criteria commonly used in RCTs due to the correspond-
ing characteristics not being reported in SOHO. Another
set of eligibility criteria not applied to define the RCT
population from our study is the one pertaining to the
risk factors associated with the safety profile intrinsic to
the investigational drug. While particular to each
individual drug (and not to schizophrenia), it further
restricts the selection of trial populations in drug
development.
Practical implications for RCT design
Quantifying the effectiveness prediction accuracy and
expected RCT results has practical implications on RCT
design. First, the impact of re-including certain patients
upon the prediction accuracy of real-world effects, as
well as on comparative effects measured in the RCT,
varied according to the exclusion criterion relaxed. As
an example, opening the trial to patients with one past
suicide attempt enables a better prediction of effective-
ness, while also providing RCT results (comparative effi-
cacy) that are less variable and closer to the real-world
effects, than opening the trial to patients with history of
alcohol abuse. In addition, opening the trial to
real-world patients with one prior suicide attempt or
shorter illness duration enables to tap into a wider
patient pool than opening the trial to patients with his-
tory of alcohol (or drug) abuse. Assuming all patients
were equally easy/difficult to recruit, the former
re-inclusion process is likely to enable faster recruit-
ment, which may be a way of preventing long accrual
times, in particular in those of disease areas where many
clinical trials are competing to recruit the same patients.
The interplay of treatment effects and recruitment speed
has been previously formalized and tested under a range
of assumptions [28]. Once treatment effects are esti-
mated on real-world data, the method by Rudser et al.
could be used to extend ours to include quantification of
recruitment speed improvement as a factor in the
selection of RCT populations. Second, for each relaxed
criterion, adding only a few patients improves predic-
tions right at the beginning of the augmentation process
(quickly achieving a 50% of the optimal improvement in
MSE by adding merely some 10–20% of patients needed
for natural augmentation, see Fig. 3), a trend that tends
to slow down as the “natural” augmentation percentage
is reached. This suggests that, for exclusion criteria that
are difficult to relax entirely, it might be worth designing
trials that incorporate only a small proportion of these
patients. This can be done, for example, by stratifying
patients at enrollment so that patients meeting
specific exclusion criteria can be re-included in
smaller proportions.
Finally, it is interesting to note that the predictions of
real-world effects using the model incorporating data
from the “RCT population” alone returned sound results
in terms of bias (< 2%) and MSE (5–6%) for both drugs
D1 and D2, thereby showing that a good prediction can
be achieved with RCT patients alone. This should motiv-
ate more researchers and drug developers to undertake
this type of modeling, still only rarely implemented
despite being advocated by many authors [11].
Applicability of the “RCT augmentation” method
While tested only on second generation antipsychotic
drugs in schizophrenia, the method is nonetheless
powerful in that it is applicable to other indications and
drug classes, with few requirements. Namely, require-
ments to implement our method to guide the selection
of the most suitable population for an upcoming drug
development trial include: (i) identifying the exclusion
criteria that could potentially be relaxed, at least
partially, such as criteria that may not absolutely need to
be applied for acute safety issues or ethical reasons; and
(ii) locating a real-world data source including suitable
patients that captures (a) variables that define the eligi-
bility criteria to be tested, (b) the trial outcomes consid-
ered as endpoints, and (c) treatments, where possible, of
the same or a similar class as the drug to be investigated
in the new trial. In addition, while not demonstrated
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herewith, this same modeling and simulation approach
is applicable to testing how different thresholds used to
define the exclusion criterion impact both trial results
and effectiveness predictions/representativeness.
Of note, our method is applicable not only to optimize
the choice of population at the trial level, as illustrated
above, but also at the clinical development program
level. For example, consider a situation where the popu-
lation destined to prove efficacy in a Phase 3 trial and its
size are already set. The question is then how to choose
the population of patients to enroll in the rest of the
program (in the same Phase 3 trial(s), in a subsequent
Phase 3b trial). I.e. which type of real-world patients to
include in priority to best train the predictive model and
estimate real-world effects? and how many of them are
needed? The “RCT augmentation” method enables to
quantify the improvement upon estimation of real-world
effects of including different population subgroups in
the clinical program. Finally, we have used an ordinal
logistic regression model with 24 patient covariates to
illustrate our “RCT augmentation” method. We did not
consider other unavailable covariates, such as type of
prior medication, nor any interactions between the
covariates or between the treatment and the covariates.
Alternative, potentially more advanced modelling
approaches may increase the power of the prediction
model. Such approaches can be readily used within our
framework.
Study limitations
Appropriate real-world data was available to us with
schizophrenia patients on second-generation antipsy-
chotics. However, it may be more difficult to find appropri-
ate real-world data to support design of a RCT on a
treatment of a completely new class or never-studied mech-
anism of action; in this case, the assumption of similar pa-
tient characteristics-to- treatment effects interactions
between drugs used in the real-word data source and the
investigational drug to be tested in the RCT would be
stronger. Also, as a limitation of using real-world data, esti-
mation of comparative efficacy in virtual RCTs may be
biased by unmeasured confounders despite our use of pro-
pensity score matching with 24 covariates [29].
It is also important to note that the improvement in
prediction accuracy (i.e., decrease in MSE) by augment-
ing the trial populations was relatively small across all
instances studied here. Three reasons can be invoked: 1)
low resolution of ΔCGI-S (this outcome provides less
information on patients’ symptoms than other
widely-used scales in schizophrenia RCTs such as the
Brief Psychiatric Rating Scale or the Positive And
Negative Syndrome Scale); 2) volunteers in RCTs may
differ from those from the “RCT population” defined here
(selection bias); and 3) it is possible that re-inclusion
criteria are not necessarily the criteria contributing the
most to increase generalizability of results from RCT.
Finally, outcomes can differ in RCT and real-world
settings not only due to differing population characteris-
tics, as investigated in our study, but also due to differ-
ent drug usage patterns. For example, RCTs typically
deploy closer monitoring, such as several exams and
physician visits within the first 3 months (e.g., in recent
trials [30–32]), which may entail higher adherence and/
or better care overall, and more research-oriented
physicians, who may have different prescribing habits to
their peers. This additional layer of difference between
the two settings would need to be incorporated when
estimating real-world effectiveness from conventional
RCTs. Our method, however, enabled us to isolate how
differences in populations between RCT and real-world
practice impact effectiveness evaluation.
Conclusion
The impact of augmenting the population of schizophrenia
RCTs in real-world patients by selectively relaxing a range
of exclusion criteria was investigated through modeling and
simulations using observational data from a large cohort of
schizophrenia patients assumed to represent routine care
practice in schizophrenia. By quantifying the impact of each
augmentation, our simulations provide a guide to measur-
ing the impact upon prediction of effectiveness and trial
statistical power from opening trials to certain types of
real-world patients in a controlled manner.
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